Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes
journal contributionposted on 2021-01-15, 08:48 authored by Francesco Zaccardi, David E Kloecker, John B Buse, Chantal Mathieu, Kamlesh Khunti, Melanie J Davies
Over the last two decades, the large majority of clinical guidelines on the treatment of hyperglycaemia in subjects with type 2 diabetes have suggested metformin as the first-line glucose-lowering treatment alongside lifestyle changes to reach personalized glycemictargets. Recently, the European Society of Cardiology (ESC) recommended using glucagon-like peptide 1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter 2 inhibitors(SGLT-2is) as first line glucose-lowering therapy in subjects with type 2 diabetes at high or very high risk of cardiovascular disease (CVD), ahead of metformin treatment, to reduce cardiovascular events.
CitationDiabetes Care 2020 Dec; dc202080. https://doi.org/10.2337/dc20-2080
Author affiliationDiabetes Research Centre, College of Life Sciences
- AM (Accepted Manuscript)